Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
HKG: 2142
Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...
Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results
China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...
Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta
Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...